Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity

OBJECTIVE: Letrozole is a non-steroidal aromatase inhibitor (AI) used to treat hormone receptor positive (HR+) breast cancer. Variability in letrozole efficacy and toxicity may be partially attributable to variable systemic drug exposure, which may be influenced by germline variants in the enzymes r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacogenet Genomics
Hlavní autoři: Hertz, Daniel L., Douglas, Julie A., Kidwell, Kelley M., Gersch, Christina L., Desta, Zeruesenay, Storniolo, Ana-Maria, Stearns, Vered, Skaar, Todd C, Hayes, Daniel F, Henry, N. Lynn, Rae, James M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8185249/
https://ncbi.nlm.nih.gov/pubmed/34096894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000429
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky